Psychopharmacology and Psychiatry Updates Pharmacogenetic Testing in Psychiatry: Help or Hype?
Jan 31, 2026
Chris Aiken, psychiatrist and editor known for clear analysis of psych med evidence. He unpacks why pharmacogenetic testing looks promising but flops in blinded trials. He contrasts single-gene actionable tests with broad panels. He calls out bias in early studies, statistical pitfalls, lab inconsistencies, and offers practical testing recommendations.
AI Snips
Chapters
Transcript
Episode notes
Panels Dilute Actionable Genetic Signals
- Pharmacogenetic panels mix a few meaningful drug-gene interactions with many irrelevant genes and medications, diluting actionable signals.
- This leads to poor evidence that commercial panels improve routine clinical care despite genetic relevance to drug metabolism.
Blinding Removes Expectation Bias
- Lack of blinding produced early positive results through expectation and placebo effects by clinicians and patients.
- When trials blinded participants around 2016, the apparent benefits disappeared across major commercial tests.
Cherry-Picked Outcomes Mislead Clinicians
- Companies cherry-pick secondary outcomes to market tests despite primary outcomes being negative.
- Data fishing and post hoc selection create misleading brochures that overstate efficacy.